Among these, a ‘‘multiple clonal driver” stage III+ subtype harbored PTEN mutations and displayed an increase in Ki67 percentage, thus suggesting PTEN status as a potential biomarker in a subset of CCRCC patients [81]. Here, PTEN is linked to nonpapillary renal cell carcinoma.